ABBOTT LABORATORIES Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value
ABBOTT LABORATORIES (ABT) had Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value of $3.02 billion as of 2016-06-30, per its 10-Q filed 2016-08-03.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue · last filed 2016-08-03
- 2016-06-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $3.02B.
- 2016-03-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $3.23B.
- 2015-09-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $2.81B.
- 2014-12-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $6.00M.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value |
|---|---|
| 2016-06-30 | $3.02B 10-Q · filed 2016-08-03 |
| 2016-03-31 | $3.23B 10-Q · filed 2016-05-04 |
| 2015-09-30 | $2.81B 10-Q · filed 2015-11-05 |
| 2014-12-31 | $6.00M 10-Q · filed 2015-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |